Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Lung Neoplasms 12Carcinoma, Hepatocellular 8Small Cell Lung Carcinoma 7Cholangiocarcinoma 7Neoplasms 6Carcinoma 6Urinary Bladder Neoplasms 5Pancreatic Neoplasms 4Neoplasm Metastasis 4Biliary Tract Neoplasms 4Triple Negative Breast Neoplasms 3Neoplasms by Site 3Gallbladder Neoplasms 3Endometrial Neoplasms 3Breast Neoplasms 3Pathologic Complete Response 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Neoplasms by Histologic Type 2Liver Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Bile Duct Neoplasms 2Adenocarcinoma 2Vaccinia 1Unresectable Hepatocellular Carcinoma 1Thoracic Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

pembrolizumab 2tremelimumab 1poly ICLC 1lenvatinib 1durvalumab 1balstilimab 1Peptides 1Pemetrexed 1Carboplatin 1Blood Specimen Collection 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diabetes Mellitus, Insulin-Dependent, 12 × durvalumab × 30 days × Clear all
NCT06564623 2026-05-08

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Recruiting
25 enrolled
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡